In the present study, we investigated the expression of CD47 in NSCLC in clinic, as well as the experimental settings; and explored the therapeutic potential of targeting CD47 with small interfering RNA (siRNA) and the underlying regulatory mechanisms, with specific focus on Cdc42, both in vitro and in vivo. The gene discussed is CDC42; the disease is non-small cell lung carcinoma.